e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical determinants and biomarkers of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum amyloid A in patients with stable chronic obstructive pulmonary disease
M. Maskey-Warzechowska (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland), T. Przybylowski (Warsaw, Poland), K. Karwat (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Chazan (Warsaw, Poland)
Source:
International Congress 2018 – Clinical determinants and biomarkers of COPD
Session:
Clinical determinants and biomarkers of COPD
Session type:
Poster Discussion
Number:
2012
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Maskey-Warzechowska (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland), T. Przybylowski (Warsaw, Poland), K. Karwat (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Chazan (Warsaw, Poland). Serum amyloid A in patients with stable chronic obstructive pulmonary disease. 2012
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Serum magnesium levels of patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003
Serum leptin levels in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 259s
Year: 2002
Plasma fibrinogen in patients with chronic obstructive pulmonary disease (COPD) with or without secondary erythrocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 586s
Year: 2005
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Association between serum YKL-40 and chronic obstructive pulmonary disease
Source: International Congress 2017 – COPD biomarkers
Year: 2017
IL-8 in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 364s
Year: 2001
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease
Source: Annual Congress 2008 - COPD
Year: 2008
Circulating adhesion molecules in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 316s
Year: 2004
Inferon administration to patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Year: 2009
Genetically elevated C-reactive protein and chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD
Year: 2009
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Circulating auto antibodies in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Pathophysiology of COPD
Year: 2008
Circulating tumor cells in chronic obstructive pulmonary disease patients
Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Year: 2011
Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Blood MCP-1 levels are increased in chronic obstructive pulmonary disease with prevalent emphysema
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Rhinovirus-infection in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 591s
Year: 2002
Prevalence of anemia of chronic disease in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept